Multiple Myeloma

The director of clinical research in the Center for Cancer Care at White Plains Hospital explained the design of the study which evaluated diabetic versus nondiabetic patients enrolled in the CONNECT Multiple Myeloma Registry.

The expert from the Levine Cancer Institute discussed the findings from an updated analysis of the phase 2 GRIFFIN Trial for patients with newly diagnosed multiple myeloma.

Wolf discussed the decisions to change therapy based on the MRD status of patients with multiple myeloma.

Selinexor (Xpovio) earned full FDA approval in combination with bortezomib (Velcade) and dexamethasone for the treatment of multiple myeloma after 1 or more prior therapies based on the phase 3 BOSTON trial.

The clinical researcher spoke about what she hopes will occur in multiple myeloma research over the next 5 years.

Wolf discusses the potential for emerging next-generation CAR T-cell treatment and the future of treating patients with multiple myeloma.

The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai discussed exciting treatment options for patients with multiple myeloma that are being presented at ASH this year.

The clinical researcher spoke about the research that she is most excited to review at ASH this year.

The ongoing phase 1/2 DREAMM-6 trial found that the addition of belantamab mafodotin to bortezomib and dexamethasone elicited high response rates and a suitable safety profile in patients with relapsed or refractory multiple myeloma.

Daratumumab plus lenalidomide, bortezomib, and dexamethasone improved response rates and depth of response in patients with transplant-eligible, newly diagnosed multiple myeloma.

TNB-383B was well tolerated and researchers saw significant responses when it was administered at a higher dose level for heavily pretreated patients with relapsed/refractory multiple myeloma.

Data presented at the 2020 ASH Meeting found talquetamab elicited a high response rate with a tolerable safety profile for patients with relapsed/refractory multiple myeloma.

The myeloma expert discussed the randomized, open label study measuring the safety and efficacy of daratumumab (Darzalex) plus RVd for patients with newly diagnosed multiple myeloma.

Cevostamab, a FcRH5xCD3 bispecific antibody, was safe and highly active when treating heavily pretreated patients with relapsed/refractory multiple myeloma, according to data presented at the 2020 ASH Annual Meeting & Exposition.

The BCMA- and CD3-targeted bispecific monoclonal antibody, demonstrated early, deep, and durable responses with acceptable safety and tolerability in patients with relapsed/refractory multiple myeloma.

An off-the-shelf CAR T-cell therapy that targets B-cell maturation antigen, ALLO-715, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.

The combination induced low rates of infusion-related reaction, and had a shorter administration duration, increasing convenience for patients and decreasing treatment burden, according to Meletios A. Dimopoulos, MD.

Patients with heavily pretreated multiple myeloma maintained durable responses with idecabtagene vicleucel, according to updated findings presented from the phase 1 CRB-401 trial.

The enriched chimeric antigen receptor T-cell therapy improved responses and prolonged duration of response in patients with relapsed/refractory multiple myeloma.

Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.

The phase 3 BOSTON study demonstrated superior PFS and ORR with selinexor (Xpovio), bortezomib (Velcade), and dexamethasone in patients with relapsed/refractory multiple myeloma.

The phase 3 BOSTON study suggested that a once-per-week combination regimen of selinexor (Xpovio), bortezomib (Velcade), and dexamethasone (Ozurdex) is an effective treatment option for patients with multiple myeloma who have received 1 to 3 previous lines of therapy.

The FDA lifted the clinical hold on the phase 1 MELANI-01 trial, which is evaluating UCARTCS1 for the treatment of patients with relapsed or refractory multiple myeloma.

“The most important takeaway here is that bridging radiation doesn’t appear to increase the risk of [cytokine release syndrome; CRS] or neurotoxicity,” said lead study author Shwetha Manjunath, MD.

Genmab recently announced positive topline results from part 2 of the Phase 3 CASSIOPEIA study examining daratumumab monotherapy as maintenance therapy to treat patients diagnosed with multiple myeloma.